Mark Shlomchik Lab

And check out the commentary by @RoserTP and @VinuesaLab: lnkd.in/ecVQm8N5

@ShlomchikLab and his team have solved a 20-year #lupus mystery! In a new @jclinicalinvest paper, they show that TLR7 & TLR9 receptors signal differently, overturning textbook assumptions & explaining their opposite effects on #autoimmune disease. lnkd.in/extqYBYR

There is still much to learn! Is there a role for IL-12 in severe infection? Is there interplay with innate immunity? How is this response negatively regulated? How can it be shut off when it causes too much damage? Does IL-12 influence B cell memory?

We are excited about new questions raised by these studies, discussed in Inaki Sanz’s N&V rdcu.be/dOzOT. EF responses are prominent in autoimmune diseases including SLE, and infection-associated immunopathogenesis including COVID-19.

Check out the N&V in @NatImmunol by Inaki Sanz about @elsner_rebecca's recent paper on how B cell intrinsic IL-12 promotes EF and suppresses GC responses via an autocrine positive feedback loop with IFNg. nature.com/articles/s4159…

Congrats to lead author @elsner_rebecca, along with Shuchi Smita and @MShlomchik on their newest study, recently published in Nature Immunology!

We conclude that ABC are a diverse and dynamic population of B cells that promote autoimmune disease. Developing approaches to target ABCs specifically, rather than all B cells, could be beneficial in lupus. (12/12) twitter.com/JExpMed/status…

Altogether this suggested that ABC undergo frequent cycles of reactivation, with some ABC progeny retaining the ABC phenotype but others terminally differentiating to PB. (11/12)

In our latest @JExpMed study, we characterized age-associated B cells (ABCs) in a model of lupus. We found unexpected heterogeneity among ABC subpopulations, identified precursor-product relationships, and showed that reducing ABCs improved renal disease. A 🧵! (1/12)